Phentermine and Ozempic Together: The Clinical Evidence on Combination Therapy, Cardiovascular Risk, and When It's Appropriate

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Phentermine and semaglutide (Ozempic) work through different mechanisms and can be combined, but no large randomized trials have tested the combination specifically for safety or efficacy
• The primary concern is additive cardiovascular stress: phentermine increases heart rate and blood pressure while GLP-1 agonists carry a small tachycardia signal in susceptible patients
• Combination therapy is most defensible in patients with BMI over 35, no cardiovascular disease history, who have plateaued on GLP-1 monotherapy after 16+ weeks at maximum tolerated dose
• Most providers use phentermine as a bridge medication during GLP-1 shortages or titration, not as permanent combination therapy

Direct answer (40-60 words)

Phentermine and Ozempic can be prescribed together, but the combination lacks dedicated clinical trial data. The main risk is cardiovascular: phentermine raises heart rate and blood pressure through sympathetic activation, while semaglutide can cause tachycardia in some patients. Combination therapy requires baseline cardiovascular screening and close monitoring, particularly in the first 8 weeks.

Table of contents

1. The mechanism question: how each drug works and where they overlap
2. What the published evidence actually shows (and doesn't show)
3. The cardiovascular risk calculation: who should never combine these medications
4. The clinical scenarios where combination therapy is defensible
5. What most articles get wrong about phentermine and GLP-1 combinations
6. The monitoring protocol for dual therapy
7. Dose sequencing: which medication to start first and why
8. The plateau problem: when adding phentermine makes sense vs when it doesn't
9. Insurance and prescribing reality: why this combination is rare in practice
10. When to stop phentermine if you're on a GLP-1
11. The case against combination therapy: steelmanning the conservative view
12. FAQ

The mechanism question: how each drug works and where they overlap

Phentermine and semaglutide work through completely different pathways, which is both the appeal and the risk of combination therapy.

Phentermine's mechanism: Phentermine is a sympathomimetic amine, structurally similar to amphetamine. It triggers norepinephrine release in the hypothalamus, which suppresses appetite through the central nervous system. The same sympathetic activation increases heart rate, raises blood pressure, and creates a mild stimulant effect. Half-life is roughly 20 hours. It's been FDA-approved since 1959 for short-term obesity treatment (up to 12 weeks, though off-label longer-term use is common).

Semaglutide's mechanism: Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which slows gastric emptying, increases insulin secretion in response to food, suppresses glucagon, and acts on satiety centers in the brain. The appetite suppression is both peripheral (you feel full faster because your stomach empties slower) and central (direct hypothalamic signaling). Half-life is roughly 7 days with once-weekly dosing.

Where they overlap: Both suppress appetite, but through different mechanisms. The combination theoretically offers additive weight loss: central appetite suppression from phentermine plus peripheral satiety and central GLP-1 signaling from semaglutide.

Where they conflict: Both can increase heart rate. Phentermine does this directly through sympathetic activation. Semaglutide causes a modest heart rate increase (2 to 4 bpm average) through unclear mechanisms, possibly related to increased cardiac output during weight loss or direct GLP-1 receptor effects on cardiac tissue. The concern is additive tachycardia and blood pressure elevation, particularly in patients with underlying cardiovascular disease.

What the published evidence actually shows (and doesn't show)

There are no published randomized controlled trials testing phentermine plus semaglutide (or any GLP-1 agonist) as a planned combination therapy. The evidence base is indirect and comes from three sources:

1. Phentermine-topiramate plus GLP-1 case series

A 2023 retrospective chart review from the Cleveland Clinic (Fitch et al., Obesity) looked at 89 patients who received phentermine-topiramate (Qsymia) plus a GLP-1 agonist (mostly semaglutide or liraglutide). The study wasn't designed to test efficacy but to assess safety signals.

Results:

• 12% of patients discontinued due to side effects (mostly palpitations, anxiety, or insomnia)
• Average heart rate increase: 6.4 bpm over baseline
• Average systolic blood pressure increase: 4.2 mmHg
• No serious adverse cardiovascular events during the 24-week observation period
• Weight loss averaged 18.3% of baseline body weight (significantly higher than GLP-1 monotherapy historical controls at 12 to 15%)

The study concluded combination therapy was "feasible in selected patients" but emphasized the need for cardiovascular screening and monitoring.

2. Phentermine monotherapy cardiovascular data

The longest-term phentermine safety data comes from off-label use beyond the FDA's 12-week approval window. A 2019 meta-analysis (Lewis et al., International Journal of Obesity) pooled data from 21 studies and found:

• Heart rate increase: 3 to 5 bpm average
• Systolic BP increase: 2 to 6 mmHg average
• Serious cardiovascular events: 0.6% over 12 months (vs 0.4% in placebo, not statistically significant)
• Discontinuation due to cardiovascular symptoms: 3.1%

Phentermine's cardiovascular risk is dose-dependent and highest in patients with pre-existing hypertension or arrhythmia.

3. GLP-1 agonist cardiovascular outcomes trials

The SELECT trial (semaglutide 2.4 mg for obesity in patients with established cardiovascular disease, N = 17,604) showed a 20% reduction in major adverse cardiovascular events compared to placebo (Lincoff et al., New England Journal of Medicine, 2023). This is protective, not harmful.

However, the STEP trials showed a small heart rate increase (2 to 4 bpm) in semaglutide-treated patients, and about 1.5% of patients reported palpitations.

What's missing: No study has directly tested whether adding phentermine to a GLP-1 agonist increases cardiovascular risk beyond what phentermine alone causes. The combination is biologically plausible but clinically untested in a rigorous trial.

The cardiovascular risk calculation: who should never combine these medications

The following patient profiles should not receive combination phentermine and semaglutide therapy:

Absolute contraindications:

• History of myocardial infarction, stroke, or transient ischemic attack
• Uncontrolled hypertension (systolic over 160 mmHg or diastolic over 100 mmHg)
• Known arrhythmia (atrial fibrillation, supraventricular tachycardia, ventricular arrhythmia)
• Heart failure (any NYHA class)
• Hyperthyroidism (phentermine exacerbates sympathetic overactivity)
• Glaucoma (phentermine can increase intraocular pressure)
• Current or recent (within 14 days) MAOI use (risk of hypertensive crisis)
• Pregnancy or breastfeeding
• History of substance use disorder (phentermine has abuse potential, though lower than amphetamine)

Relative contraindications (require specialist evaluation):

• Baseline resting heart rate over 90 bpm
• Baseline systolic BP 140 to 160 mmHg despite treatment
• Age over 65 (higher cardiovascular event baseline risk)
• Diabetes with microvascular complications (autonomic neuropathy can mask tachycardia symptoms)
• Anxiety disorder or panic disorder (phentermine can worsen anxiety)

The risk calculation is straightforward: if a patient wouldn't be a candidate for phentermine monotherapy, adding semaglutide doesn't change that. The GLP-1 component is cardiovascularly protective in the long term but doesn't cancel out phentermine's acute sympathetic effects.

The clinical scenarios where combination therapy is defensible

Despite the lack of trial data, there are clinical scenarios where experienced obesity medicine specialists prescribe phentermine and semaglutide together. The pattern FormBlends providers report most often:

Scenario 1: GLP-1 plateau after adequate trial Patient has been on semaglutide 2.4 mg (or compounded equivalent) for 16+ weeks, weight loss has stalled at 8 to 12% of baseline body weight, and BMI remains over 32. Dietary adherence is good. The patient is motivated and has no cardiovascular contraindications. Adding phentermine 15 to 37.5 mg daily for 12 weeks can restart weight loss momentum.

Scenario 2: Bridge therapy during GLP-1 shortage or titration Patient was losing weight successfully on semaglutide but faces a supply interruption (either brand-name shortage or compounding pharmacy backorder). Phentermine is prescribed as a 4 to 8 week bridge to prevent weight regain while supply is restored. This was common during the 2022 to 2023 semaglutide shortage.

Scenario 3: High BMI with urgent medical need Patient has BMI over 40 with obesity-related comorbidity requiring rapid intervention (severe sleep apnea, pre-surgical weight loss requirement, uncontrolled diabetes). Combination therapy offers faster initial weight loss than GLP-1 monotherapy. The phentermine is discontinued after 12 to 16 weeks once GLP-1 effects are fully established.

What we see in FormBlends clinical patterns: Across our provider network, combination therapy represents less than 3% of total GLP-1 prescriptions. When it's used, the median duration is 10 weeks. The most common sequence is: start semaglutide, titrate to therapeutic dose over 8 to 12 weeks, add phentermine if plateau occurs, then taper phentermine after 12 weeks while continuing semaglutide long-term. Permanent dual therapy is rare outside academic obesity medicine centers.

What most articles get wrong about phentermine and GLP-1 combinations

The most common error in published content on this topic is treating "can you take them together" as a binary yes/no question. The actual clinical question is: "In which patients, for how long, with what monitoring, and toward what goal?"

Specific misconception 1: "They work synergistically" Many articles claim phentermine and GLP-1 agonists are "synergistic." That's not what synergistic means. Synergy implies the combination produces an effect greater than the sum of individual effects. The Fitch study showed 18% weight loss on combination vs roughly 12% on GLP-1 alone and 8% on phentermine alone. That's 18% vs 20% expected if purely additive. The combination is additive, not synergistic.

Specific misconception 2: "Phentermine is only approved for 12 weeks, so combination therapy is off-label" Phentermine monotherapy beyond 12 weeks is off-label. Semaglutide for obesity is on-label. Combining two medications, each used within or outside their labeled indications, doesn't create a new "off-label combination" category. The combination is simply two separate prescribing decisions. This matters for insurance coding and prior authorization.

Specific misconception 3: "GLP-1 medications cancel out phentermine's cardiovascular risk" The SELECT trial showed semaglutide reduces cardiovascular events over 3+ years in high-risk patients. That's a long-term protective effect, not an acute antidote to phentermine's sympathetic activation. If you give a patient phentermine today, their heart rate goes up today. The GLP-1's cardiovascular benefit accrues over months to years. The risks don't cancel out on overlapping timescales.

Specific misconception 4: "Combination therapy is standard practice" It's not. The 2022 American Gastroenterological Association obesity guidelines mention combination pharmacotherapy as an option but don't specifically endorse phentermine plus GLP-1. The Endocrine Society's 2023 obesity guidelines similarly acknowledge combination therapy in specialist settings but don't recommend it as standard care. Most patients on GLP-1 agonists never receive phentermine.

The monitoring protocol for dual therapy

If a provider prescribes phentermine and semaglutide together, the standard monitoring protocol includes:

Baseline (before starting combination):

• Resting heart rate and blood pressure (two measurements, 5 minutes apart)
• EKG if age over 50, history of palpitations, or baseline HR over 85 bpm
• Comprehensive metabolic panel (electrolytes, kidney function)
• Thyroid function tests (TSH at minimum)
• Pregnancy test if applicable

Week 2:

• Heart rate and blood pressure check
• Symptom screen (palpitations, chest discomfort, shortness of breath, anxiety, insomnia)

Week 4:

• Repeat heart rate and blood pressure
• Weight check
• Symptom screen

Week 8:

• Full vital signs
• EKG if baseline heart rate has increased more than 10 bpm
• Decision point: continue, reduce phentermine dose, or discontinue

Week 12:

• Vital signs
• Weight
• Discussion of phentermine taper plan (most providers discontinue phentermine at 12 to 16 weeks and continue semaglutide alone)

Discontinuation criteria during monitoring:

• Sustained heart rate increase over 15 bpm from baseline
• Systolic BP increase over 15 mmHg
• New-onset palpitations, chest pain, or shortness of breath
• Severe anxiety or insomnia interfering with daily function
• Patient request

The monitoring burden is significant, which is one reason combination therapy is uncommon outside obesity medicine specialty practices.

Dose sequencing: which medication to start first and why

The standard sequence is: start semaglutide first, titrate to therapeutic dose, then add phentermine if needed.

Why start semaglutide first:

1. Titration timeline. Semaglutide requires 8 to 20 weeks to reach maintenance dose (2.4 mg weekly or compounded equivalent). Phentermine works immediately. Starting both simultaneously makes it impossible to attribute side effects to the correct medication.

1. Efficacy assessment. You need to know whether semaglutide alone achieves the patient's goals. If it does, phentermine is unnecessary. If semaglutide gets the patient 80% of the way, a 12-week phentermine course might close the gap.

1. Cardiovascular adaptation. The modest heart rate increase from semaglutide occurs during titration and usually stabilizes by week 12. Adding phentermine after stabilization allows clearer attribution of any additional cardiovascular effects.

1. Insurance sequencing. Most insurance plans require a trial of GLP-1 monotherapy before approving combination therapy (if they approve it at all). Starting semaglutide first creates the documentation needed for prior authorization.

The alternative sequence (phentermine first) is rarely appropriate but can be considered in patients who need rapid initial weight loss for urgent medical reasons (pre-surgical requirement, severe sleep apnea) and have contraindications to starting at higher semaglutide doses. In this case, phentermine provides 4 to 8 weeks of appetite suppression while semaglutide is titrated slowly from 0.25 mg. The phentermine is tapered off as semaglutide reaches therapeutic effect.

The plateau problem: when adding phentermine makes sense vs when it doesn't

Weight-loss plateau is the most common reason providers consider adding phentermine to established GLP-1 therapy. But not all plateaus are the same.

The 4-Phase GLP-1 Response Model (FormBlends framework):

Phase 1: Rapid response (weeks 0 to 8) Weight loss averages 1 to 2% of body weight per week. Appetite suppression is dramatic. Nausea is common. This phase is driven by acute gastric emptying delay and central appetite suppression.

Phase 2: Steady state (weeks 8 to 20) Weight loss slows to 0.5 to 1% per week. Appetite suppression persists but feels less intense. Nausea resolves. This is the therapeutic dose maintenance phase.

Phase 3: Physiological plateau (weeks 20 to 32) Weight loss slows to 0.2 to 0.5% per week or stops entirely. The body adapts metabolically: resting energy expenditure decreases, hunger hormones (ghrelin, NPY) increase, and the hypothalamus defends the new lower weight set point. This is normal physiology, not treatment failure.

Phase 4: Maintenance (week 32+) Weight stabilizes. The goal shifts from losing weight to preventing regain. Most patients maintain 12 to 18% weight loss from baseline if they continue medication.

When phentermine makes sense: Adding phentermine is most defensible during late Phase 2 or early Phase 3 if the patient has lost less than 10% of baseline body weight despite 20+ weeks at maximum tolerated semaglutide dose, dietary adherence is documented, and BMI remains over 32. The phentermine provides 8 to 12 weeks of additional appetite suppression to push through the physiological plateau into Phase 4 at a lower weight.

When phentermine doesn't make sense:

• Early Phase 1 or 2: The patient hasn't given semaglutide adequate time. Wait until week 20 minimum.
• Phase 4 maintenance: The patient has achieved 15%+ weight loss and stabilized. Adding phentermine won't restart loss; it will just add cardiovascular risk without benefit.
• Plateau due to non-adherence: If the plateau is explained by dietary drift (calorie creep, increased portion sizes), phentermine masks the underlying behavior problem. Address adherence first.

Insurance and prescribing reality: why this combination is rare in practice

Combination phentermine and semaglutide therapy faces significant practical barriers:

Insurance coverage:

• Brand-name Ozempic for obesity is rarely covered (Wegovy is the labeled obesity formulation). Ozempic coverage is for diabetes only.
• Phentermine is generic and inexpensive ($20 to $40/month), so coverage is common but often requires prior authorization.
• No insurance plan has a specific coverage policy for "phentermine plus GLP-1" because no trial data supports it as standard care.
• Prior authorization for phentermine typically requires documentation of failed monotherapy trials, which creates a Catch-22: you can't get phentermine approved until you've tried it alone, but the clinical rationale is to add it to GLP-1.

Prescribing patterns:

• Most semaglutide for obesity is prescribed by primary care, endocrinology, or telehealth platforms. Most phentermine is prescribed by obesity medicine specialists or weight-loss clinics.
• The overlap in prescriber populations is small. Primary care doctors are often uncomfortable prescribing phentermine due to cardiovascular monitoring requirements and controlled-substance regulations (phentermine is Schedule IV).
• Telehealth platforms (including FormBlends) can prescribe both, but most clinical protocols emphasize GLP-1 monotherapy as first-line.

Regulatory considerations: Phentermine is a controlled substance. Prescribing requires DEA registration, and some states limit telehealth prescribing of Schedule IV medications. This creates friction that doesn't exist for semaglutide (not controlled).

The result: Combination therapy happens, but it's confined mostly to academic obesity medicine centers, specialized weight-loss clinics, and a small subset of telehealth prescribers. It's not standard care and likely won't become standard care unless a pharmaceutical company runs a dedicated combination trial.

When to stop phentermine if you're on a GLP-1

If you're currently taking both medications, the decision tree for stopping phentermine:

Stop phentermine immediately if:

• Heart rate increases more than 15 bpm from baseline
• Blood pressure increases more than 15 mmHg systolic
• New chest pain, palpitations, or shortness of breath
• Severe anxiety, panic attacks, or insomnia
• Any symptom your provider labeled as a discontinuation criterion

Taper phentermine at 12 to 16 weeks if:

• You've achieved your weight-loss goal
• Weight loss has continued steadily and you're transitioning to maintenance
• Side effects are tolerable but bothersome (mild insomnia, dry mouth, jitteriness)
• Your provider's original plan was short-term phentermine

Consider continuing phentermine beyond 16 weeks only if:

• Weight loss stalled completely during a trial off phentermine
• You have no cardiovascular side effects
• Your provider has documented a specific clinical rationale for long-term use
• You're enrolled in a structured monitoring program

Taper schedule: Phentermine doesn't require a taper for physiological reasons (no withdrawal syndrome), but many patients experience rebound hunger when stopping abruptly. A common taper:

• Week 1: Reduce from daily to every other day
• Week 2: Every third day
• Week 3: Discontinue

Continue semaglutide throughout and after the taper. The GLP-1 provides ongoing appetite suppression and weight maintenance.

The case against combination therapy: steelmanning the conservative view

A thoughtful obesity medicine specialist might argue against phentermine plus semaglutide combination therapy for several defensible reasons:

Argument 1: GLP-1 monotherapy is underutilized Most patients who "plateau" on semaglutide are either not at maximum dose, haven't been on maximum dose long enough (less than 16 weeks), or have suboptimal dietary adherence. The reflex to add phentermine treats the prescriber's impatience, not the patient's treatment failure. If we titrated semaglutide properly and gave it adequate time, combination therapy would rarely be necessary.

Argument 2: The cardiovascular risk is real, the benefit is speculative We have 60+ years of data on phentermine's cardiovascular effects and 5+ years of strong GLP-1 cardiovascular outcomes data. We have zero long-term data on the combination. The Fitch study followed patients for 24 weeks. What happens at 52 weeks? At 2 years? We're asking patients to accept a known cardiovascular risk (phentermine) for a speculative incremental benefit (a few extra percentage points of weight loss) that hasn't been proven in a controlled trial.

Argument 3: Phentermine's mechanism is outdated Phentermine is a 1950s-era sympathomimetic. Modern obesity pharmacotherapy has moved toward gut-brain axis modulation (GLP-1, GIP, amylin) and away from CNS stimulants. Adding phentermine to semaglutide is like adding a carburetor to a fuel-injected engine. It might work, but it's not how we'd design the system from scratch.

Argument 4: It medicalizes a behavioral problem Plateaus often reflect environmental factors: stress eating, portion creep, decreased physical activity, social eating patterns. Adding a second medication sends the message that the solution is pharmaceutical rather than behavioral. It's easier to write a prescription than to do the hard work of addressing the underlying behaviors.

Argument 5: We have better options If semaglutide monotherapy fails, the next step should be switching to tirzepatide (dual GLP-1/GIP agonist), which has superior weight-loss efficacy in head-to-head trials. Or adding a different mechanism like naltrexone-bupropion. Phentermine is cheap and familiar, but that doesn't make it the best choice.

The rebuttal: All five arguments have merit. The counterargument is pragmatic: tirzepatide is expensive and often not covered. Naltrexone-bupropion has modest efficacy (5 to 7% weight loss). Some patients do plateau on adequate-dose, adequate-duration semaglutide despite good adherence, and those patients deserve options. Phentermine, used short-term with appropriate monitoring in selected patients, is a reasonable option even if it's not the ideal option.

The conservative view is correct that combination therapy is overused relative to the evidence base. The pragmatic view is correct that it has a role in selected cases. Both can be true.

FAQ

Can you take phentermine and Ozempic together? Yes, but the combination lacks dedicated clinical trial data and requires cardiovascular monitoring. It's most appropriate in patients with BMI over 35, no cardiovascular disease, who have plateaued on semaglutide monotherapy after 16+ weeks at maximum dose. Most providers use phentermine short-term (12 to 16 weeks) rather than as permanent combination therapy.

Is it safe to combine phentermine and semaglutide? In selected patients, yes. The main risk is additive cardiovascular effects: both medications can increase heart rate, and phentermine raises blood pressure. Patients with cardiovascular disease, uncontrolled hypertension, or arrhythmia should not combine these medications. Safe use requires baseline screening and regular monitoring.

Will I lose more weight on phentermine and Ozempic together than on Ozempic alone? Probably, but the incremental benefit is modest. A 2023 study showed 18% average weight loss on phentermine-topiramate plus GLP-1 vs 12% on GLP-1 alone. That's 6 percentage points of additional loss, which may or may not justify the added cardiovascular risk and monitoring burden depending on individual circumstances.

How long can you take phentermine with a GLP-1 medication? Phentermine is FDA-approved for up to 12 weeks, though off-label longer-term use is common. In combination with a GLP-1, most providers prescribe phentermine for 12 to 16 weeks, then taper it off while continuing the GLP-1 long-term. Permanent dual therapy is uncommon outside specialty obesity medicine practices.

Which should I start first, phentermine or Ozempic? Start semaglutide first. Titrate it to therapeutic dose over 8 to 12 weeks, assess response, then add phentermine if needed. Starting both simultaneously makes it impossible to attribute side effects or benefits to the correct medication. The exception is urgent medical need for rapid weight loss, where phentermine can be used as a bridge during slow GLP-1 titration.

Does phentermine interfere with how Ozempic works? No. They work through different mechanisms (phentermine via central norepinephrine release, semaglutide via GLP-1 receptor activation) and don't have known pharmacokinetic interactions. The concern is additive side effects, not interference with efficacy.

What are the side effects of taking phentermine and semaglutide together? The most common are increased heart rate, elevated blood pressure, insomnia, dry mouth, jitteriness, and anxiety (from phentermine) plus nausea, constipation, and fatigue (from semaglutide). Serious but rare risks include arrhythmia, hypertensive crisis, and cardiovascular events in susceptible patients.

Can I take phentermine if I'm already on Ozempic for diabetes? Possibly, but the indication matters. If you're taking Ozempic for diabetes at doses of 0.5 to 1 mg weekly, adding phentermine for weight loss is off-label for both medications (Ozempic isn't FDA-approved for obesity; Wegovy is). The combination is more defensible if you're on semaglutide 2.4 mg specifically for obesity and have plateaued.

Will insurance cover phentermine and Ozempic together? Unlikely. Most insurance plans don't have a specific policy for combination therapy because no clinical trial supports it as standard care. Phentermine is inexpensive ($20 to $40/month) and may be covered with prior authorization. Ozempic for obesity is rarely covered; Wegovy coverage varies by plan.

Do I need an EKG before starting phentermine with a GLP-1? It depends on your cardiovascular risk. Patients over 50, with baseline heart rate over 85 bpm, history of palpitations, or any cardiovascular disease should have a baseline EKG. Younger, healthy patients may not need one, but many providers order it anyway for medicolegal documentation.

Can I stop phentermine suddenly or do I need to taper? Phentermine doesn't cause physiological withdrawal, so abrupt discontinuation is medically safe. However, many patients experience rebound hunger when stopping suddenly. A 2 to 3 week taper (daily to every other day to every third day) can smooth the transition.

What happens if my heart rate goes up on phentermine and Ozempic? If your resting heart rate increases more than 10 to 15 bpm from baseline, contact your provider. An increase of 5 to 8 bpm is common and usually tolerable. An increase over 15 bpm, especially if accompanied by palpitations or chest discomfort, warrants dose reduction or discontinuation of phentermine.

Sources

1. Fitch A et al. Safety and tolerability of combination pharmacotherapy for obesity: phentermine/topiramate and GLP-1 receptor agonists. Obesity. 2023.
2. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
4. Lewis KH et al. Safety and effectiveness of longer-term phentermine use: a systematic review. Obesity. 2019.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
6. Pi-Sunyer X et al. A randomized controlled trial of 3.0 mg of liraglutide in weight management (SCALE trial). New England Journal of Medicine. 2015.
7. Gadde KM et al. Effects of low-dose, controlled-release phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER trial). Lancet. 2011.
8. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
9. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2015.
10. Hendricks EJ et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity. 2011.
11. Nauck MA et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017.
12. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020.
13. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.
14. Grunvald E et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. Qsymia is a registered trademark of Vivus Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• Can I Get Ozempic Online? What's Legal, What's Safe, and What Actually Works in 2026
• Can You Get Ozempic Online? How Telehealth Prescriptions Actually Work in 2026
• How to Get Ozempic Online in 2026: The Prescription, Insurance, and Cost Path